Legislation related to prescription drug prices, access to epinephrine in schools, childcare, and other community settings
2026 · 1st Quarter (Jan 1 - Mar 31)
KALEO
Filed by WINNING STRATEGIES WASHINGTON.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 18, 2026
- Income
- $20,000.00
- Expenses
- Not reported
- Registrant
- WINNING STRATEGIES WASHINGTON
- Client
- KALEO
- Filing UUID
- ab1f35f8-cb29-459b-aad4-4b594b2ef707
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Pharmaceutical drug development, including epinephrine for anaphylaxis; drug access and affordability issues
Medical countermeasures research and development
Medical countermeasures research and development
FAA reauthorization provisions related to emergency medicine.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.